EWEmilie M. Wigdor

Emilie M. Wigdor

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Emilie M. Wigdor has a total of 443 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Brain disorder mechanisms and therapeutic targets identified from developmental, cell-specific gene regulation

    by Narjes Rohani, Rothem Kovner, Yuting Liu, Antonio Garcia Guerra, Theodora Markati, Soo-Whee Kim, Yujin Kim, Qi Xu, Emilie M Wigdor, Jakob Weiss, et al.

    Genetic variation influences brain physiology and disease across cell types and development. We integrated whole-genome sequencing, bulk RNA sequencing, and single-nucleus multiome profiling from 231 human dorsolateral prefrontal cortex donors spanning six postconceptional weeks to 92 years. Across 24 brain-related traits, neurodevelopmental and psychiatric genetic risk was enriched in neuronal transcriptomic and chromatin profiles, whereas neurodegenerative risk was enriched in microglia. Thousands of expression, chromatin accessibility, and splicing quantitative trait loci revealed developmental and cell-type-specific regulatory effects. Colocalization linked multiple sclerosis risk to AHI1 expression in prenatal neurons and problematic alcohol use to GPX1 expression in postnatal glia. Leveraging dynamic cis-regulatory elements, we identified therapeutic candidates for haploinsufficient neurodevelopmental disorders, including a SOX5 enhancer whose CRISPR activation increased transcript and protein abundance. Together, these findings establish a publicly accessible genomic resource for resolving the developmental and cellular contexts of genetic risk and identifying therapeutic targets in the human brain.

  • Open Access

    Molecular Dynamics of Brodmann Area 22 in Development and Autism

    by Varun Suresh, Emilie M. Wigdor, Tomasz J. Nowakowski, See Pdf

    Challenges in verbal communication are a prominent feature of autism. However, gene regulatory programs in speech-related cortical regions remain poorly characterized. In parallel, it remains unclear whether the heterogeneous genetic factors underlying autism converge on shared neurobiological mechanisms. To address these gaps, we generated paired transcriptomic and epigenomic data from post-mortem human brains across 100 donors. We show that transcriptional differences in the speech-related Brodmann Area 22 in individuals with neurodevelopmental conditions, including autism, are strongest among those with a known genetic diagnosis. A similar but attenuated signature is observed in those without a genetic diagnosis. These transcriptional differences are most pronounced in neurons, with glutamatergic L4/5 intratelencephalic-neurons affected across multiple modalities. Finally, multimodal analysis implicates altered RFX3-dependent networks as a key hub in autism, particularly among L4/5 intratelencephalic-neurons in non-verbal individuals. Together, our study identifies regulatory architecture linking chromatin state, transcriptional output, and variation in verbal ability in autism.

  • Open Access

    Genome-wide association studies of infant and toddler temperament in European and multi-ancestry populations

    by Anja Hollowell, Anna Gui, Emilie Wigdor, Morgan J. Morgan, Laurie J. Hannigan, Elizabeth C. Corfield, René Pool, Susanne Bruins, Helga Ask, Christel M. Middeldorp, et al.

    Early temperament, such as socio-emotional development and activity level, varies widely, yet its underlying biological associations are not understood. We identified genetic variation associated with infant and toddler temperament using genome-wide association meta-analyses. We studied parent-rated emotionality, activity, shyness and sociability ( n = 43,963–72,663) in the second and third postnatal years and a cross-age average. Cross-age single nucleotide polymorphism heritabilities for emotionality, activity, shyness and sociability were 6.79% (95% confidence interval (CI), (4.71%, 8.87%)), 9.55% (95% CI, (7.04%, 12.06%)), 15.26% (95% CI, (12.24%, 18.28%)) and 3.42% (95% CI, (1.30%, 5.54%)), respectively. Ten genome-wide significant loci were discovered. Two loci colocalized with expression quantitative trait loci in the adult cortex: RHEBL1 (posterior probability, 0.93; associated with activity) and MR1 (posterior probability, 0.99; with emotionality). Genetic correlations were observed between early temperament and later outcomes, such as emotionality and adult neuroticism, activity and attention deficit/hyperactivity disorder (ADHD), sociability and autism, and shyness and adult extraversion. Multi-ancestry ( n = 56,083–78,894) and European-ancestry analyses gave similar results. Infant and toddler temperament is associated with genetic variation and shows genetic continuity with later outcomes.


  • Open Access

    Genome-scale functional mapping of the mammalian whole brain with in vivo Perturb-seq

    by Tuo Shi, Maria Korshunova, Seoyeon Kim, David DeTomaso, Xinhe Zheng, Lavanya Vishvanath, Thokozile Nyasulu, Nhan Huynh, Alexander Sun, Patrick C. Thompson, et al.

    Functional genomics studies have provided critical insights into cell type-specific gene regulatory programs, but to date most have been conducted in wild-type tissues or cell cultures. Here, we present a gene expression functional atlas across the mouse brain. We use an enhanced in vivo Perturb-seq platform to analyze transcriptome-wide responses to loss of 1,947 disease-associated genes, profiling over 7.7 million cells spanning major brain regions and neuronal populations. We find striking cell-type-specific essentiality and transcriptional programs and show that closely related disease genes such as two NMDA receptor subunits can drive opposing transcriptional programs. Together, this work reveals insights into the genetics and mechanisms of neurodevelopmental, psychiatric, and neurodegenerative diseases in vivo, paving the way for the design of future genetic medicine.


  • Open Access

    Genome-wide association meta-analysis of age at onset of walking in over 70,000 infants of European ancestry

    by Anna Gui, Anja Hollowell, Emilie M. Wigdor, Morgan J. Morgan, Laurie J. Hannigan, Elizabeth C. Corfield, Veronika Odintsova, Jouke-Jan Hottenga, Andrew Wong, René Pool, et al.

    Age at onset of walking is an important early childhood milestone which is used clinically and in public health screening. In this genome-wide association study meta-analysis of age at onset of walking (N = 70,560 European-ancestry infants), we identified 11 independent genome-wide significant loci. SNP-based heritability was 24.13% (95% confidence intervals = 21.86–26.40) with ~11,900 variants accounting for about 90% of it, suggesting high polygenicity. One of these loci, in gene RBL2, co-localized with an expression quantitative trait locus (eQTL) in the brain. Age at onset of walking (in months) was negatively genetically correlated with ADHD and body-mass index, and positively genetically correlated with brain gyrification in both infant and adult brains. The polygenic score showed out-of-sample prediction of 3–5.6%, confirmed as largely due to direct effects in sib-pair analyses, and was separately associated with volume of neonatal brain structures involved in motor control. This study offers biological insights into a key behavioural marker of neurodevelopment.


  • Top Cited Papers
    Open Access

    Examining the role of common variants in rare neurodevelopmental conditions

    by Qin Qin Huang, Emilie M. Wigdor, Daniel S. Malawsky, Patrick Campbell, Kaitlin E. Samocha, V. Kartik Chundru, Petr Danecek, Sarah Lindsay, Thomas Marchant, Mahmoud Koko, et al.

    Although rare neurodevelopmental conditions have a large Mendelian component1, common genetic variants also contribute to risk2,3. However, little is known about how this polygenic risk is distributed among patients with these conditions and their parents nor its interplay with rare variants. It is also unclear whether polygenic background affects risk directly through alleles transmitted from parents to children, or whether indirect genetic effects mediated through the family environment4 also play a role. Here we addressed these questions using genetic data from 11,573 patients with rare neurodevelopmental conditions, 9,128 of their parents and 26,869 controls. Common variants explained around 10% of variance in risk. Patients with a monogenic diagnosis had significantly less polygenic risk than those without, supporting a liability threshold model5. A polygenic score for neurodevelopmental conditions showed only a direct genetic effect. By contrast, polygenic scores for educational attainment and cognitive performance showed no direct genetic effect, but the non-transmitted alleles in the parents were correlated with the child’s risk, potentially due to indirect genetic effects and/or parental assortment for these traits4. Indeed, as expected under parental assortment, we show that common variant predisposition for neurodevelopmental conditions is correlated with the rare variant component of risk. These findings indicate that future studies should investigate the possible role and nature of indirect genetic effects on rare neurodevelopmental conditions, and consider the contribution of common and rare variants simultaneously when studying cognition-related phenotypes.


  • Open Access

    Substantial role of rare inherited variation in individuals with developmental disorders

    by Kaitlin E. Samocha, Vignesh Kartik Chundru, Jack M. Fu, Eugene J. Gardner, Petr Danecek, Emilie M. Wigdor, Daniel S. Malawsky, Sarah J. Lindsay, Patrick Campbell, Tarjinder Singh, et al.

    While the role of de novo and recessively-inherited coding variation in risk for rare developmental disorders (DDs) has been well established, the contribution of damaging variation dominantly-inherited from parents is less explored. Here, we investigated the contribution of rare coding variants to DDs by analyzing 13,452 individuals with DDs, 18,613 of their family members, and 3,943 controls using a combination of family-based and case/control analyses. In line with previous studies of other neuropsychiatric traits, we found a significant burden of rare (allele frequency < 1×10 -5 ) predicted loss-of-function (pLoF) and damaging missense variants, the vast majority of which are inherited from apparently unaffected parents. These predominantly inherited burdens are strongest in DD-associated genes or those intolerant of pLoF variation in the general population, however we estimate that ∼10% of the excess of these variants in DD cases is found within the DD-associated genes, implying many more risk loci are yet to be identified. We found similar, but attenuated, burdens when comparing the unaffected parents of individuals with DDs to controls, indicating that parents have elevated risk of DDs due to these rare variants, which are overtransmitted to their affected children. We estimate that 6-8.5% of the population attributable risk for DDs are due to rare pLoF variants in those genes intolerant of pLoF variation in the general population. Finally, we apply a Bayesian framework to combine evidence from these analyses of rare, mostly-inherited variants with prior de novo mutation burden analyses to highlight an additional 25 candidate DD- associated genes for further follow up.


  • Open Access

    Genome-wide association meta-analysis of age at onset of walking

    by Anna Gui, Anja Hollowell, Emilie M. Wigdor, Morgan J. Morgan, Laurie J. Hannigan, Elizabeth C. Corfield, Veronika Odintsova, Jouke-Jan Hottenga, Andrew Wong, René Pool, et al.

    Onset of walking is a developmental milestone with wide individual differences and high heritability in humans. In this genome-wide association study meta-analysis of age at onset of walking (N=70,560 European-ancestry infants), SNP-based heritability was 24.13% (SE=1.16%) with ∼11.9K variants accounting for about 90% of it, suggesting high polygenicity. We identified 11 independent genome-wide significant loci, including a “double hit” haplotype in which both decreased expression of RBL2 and a potentially deleterious missense variant in RBL2 are associated with delayed walking. Age at onset of walking (in months) was negatively genetically correlated with ADHD and BMI, and positively genetically correlated with intelligence, educational attainment, and adult brain gyrification. The polygenic score showed out-of-sample prediction of 3-5.6%, confirmed to be largely due to direct effects in sib-pair analyses, and was associated with volume of neonatal brain structures involved in motor control. This offers new biological insights of clinical relevance into neurodevelopment.


  • Open Access

    Dissecting the contribution of common variants to risk of rare neurodevelopmental conditions

    by Qin Qin Huang, Emilie M Wigdor, Patrick Campbell, Daniel S Malawsky, Kaitlin E Samocha, V Kartik Chundru, Petr Danecek, Sarah Lindsay, Thomas Marchant, Mahmoud Koko Musa, et al.

    Although rare neurodevelopmental conditions have a large Mendelian component, common genetic variants also contribute to risk. However, little is known about how this polygenic risk is distributed among patients with these conditions and their parents, its interplay with rare variants, and whether parents’ polygenic background contributes to their children’s risk beyond the direct effect of variants transmitted to the child (i.e. via indirect genetic effects potentially mediated through the prenatal environment or ‘genetic nurture’). Here, we addressed these questions using genetic data from 11,573 patients with rare neurodevelopmental conditions, 9,128 of their parents and 26,869 controls. Common variants explained ∼10% of variance in overall risk. Patients with a monogenic diagnosis had significantly less polygenic risk than those without, supporting a liability threshold model, while both genetically undiagnosed patients and diagnosed patients with affected parents had significantly more risk than controls. In a trio-based model, using a polygenic score for neurodevelopmental conditions, the transmitted but not the non-transmitted parental alleles were associated with risk, indicating a direct genetic effect. In contrast, we observed no direct genetic effect of polygenic scores for educational attainment and cognitive performance, but saw a significant correlation between the child’s risk and non-transmitted alleles in the parents, potentially due to indirect genetic effects and/or parental assortment for these traits. Indeed, as expected under parental assortment, we show that common variant predisposition for neurodevelopmental conditions is correlated with the rare variant component of risk. Our findings thus suggest that future studies should investigate the possible role and nature of indirect genetic effects on rare neurodevelopmental conditions, and consider the contribution of common and rare variants simultaneously when studying cognition-related phenotypes.


  • Open Access

    AlphaMissense is better correlated with functional assays of missense impact than earlier prediction algorithms

    by Alicia Ljungdahl, Sayeh Kohani, Nicholas F. Page, Eloise S. Wells, Emilie M. Wigdor, Shan Dong, Stephan J. Sanders

    Missense variants that alter a single amino acid in the encoded protein contribute to many human disorders but pose a substantial challenge in interpretation. Though these variants can be reliably identified through sequencing, distinguishing the clinically significant ones remains difficult, such that “Variants of Unknown Significance” outnumber those classified as “Pathogenic” or “Likely Pathogenic.” Numerous in silico approaches have been developed to predict the functional impact of missense variants to inform clinical interpretation, the latest being AlphaMissense, which uses artificial intelligence methods trained on predicted protein structure. To independently assess the performance of AlphaMissense and 38 other predictors of missense severity, we compared predictions to data from multiplexed assays of variant effect (MAVE). MAVE experiments generate almost every possible individual amino acid change in a gene and measure their functional impact using a high-throughput assay. Assessing 17,696 variants across five genes ( DDX3X, MSH2, PTEN, KCNQ4 , and BRCA1 ), we find that AlphaMissense is consistently one of the top five algorithms based on correlation with functional impact and is the best-correlated algorithm for two genes. We conclude that AlphaMissense represents the current best-in-class predictor by this metric; however, the improvement over other algorithms is modest. We note that multiple missense predictors, including AlphaMissense, appear to overcall variants as pathogenic despite minimal functional impact and that substantially more high-quality training data, including consistently analyzed patient cohorts and MAVE analyses, are required to improve accuracy.